An Aspirin a Day: New Pharmacological Developments and Cancer Chemoprevention
Open Access
- 20 January 2023
- journal article
- review article
- Published by Annual Reviews in Annual Review of Pharmacology and Toxicology
- Vol. 63 (1) , 165-186
Abstract
Chemoprevention refers to the use of natural or synthetic agents to reverse, suppress, or prevent the progression or recurrence of cancer. A large body of preclinical and clinical data suggest the ability of aspirin to prevent precursor lesions and cancers, but much of the clinical data are inferential and based on descriptive epidemiology, case control, and cohort studies or studies designed to answer other questions (e.g., cardiovascular mortality). Multiple pharmacological, clinical, and epidemiologic studies suggest that aspirin can prevent certain cancers but may also cause other effects depending on the tissue or disease and organ site in question. The best-known biological targets of aspirin are cyclooxygenases, which drive a wide variety of functions, including hemostasis, inflammation, and immune modulation. Newly recognized molecular and cellular interactions suggest additional modifiable functional targets, and the existence of consensus molecular cancer subtypes suggests that aspirin may have differential effects based on tumor heterogeneity. This review focuses on new pharmacological developments and innovations in biopharmacology that clarify the potential role of aspirin in cancer chemoprevention.Keywords
This publication has 132 references indexed in Scilit:
- Aspirin Use, TumorPIK3CAMutation, and Colorectal-Cancer SurvivalNew England Journal of Medicine, 2012
- Aspirin in the Chemoprevention of Colorectal Neoplasia: An OverviewCancer Prevention Research, 2012
- Coxibs and Other Nonsteroidal Anti-Inflammatory Drugs in Animal Models of Cancer ChemopreventionCancer Prevention Research, 2011
- COX-2 Blockade Suppresses Gliomagenesis by Inhibiting Myeloid-Derived Suppressor CellsCancer Research, 2011
- Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trialsThe Lancet, 2010
- Modified heparins inhibit integrin αIIbβ3 mediated adhesion of melanoma cells to platelets in vitro and in vivoInternational Journal of Cancer, 2009
- Aspirin and the Risk of Colorectal Cancer in Relation to the Expression of COX-2New England Journal of Medicine, 2007
- Vasoactive prostanoids are generated from arachidonic acid by COX-1 and COX-2 in the mouseAmerican Journal of Physiology-Heart and Circulatory Physiology, 2005
- Studies on the role of platelet eicosanoid metabolism and integrin αIIbβ3 in tumor‐cell‐induced platelet aggregationInternational Journal of Cancer, 1993
- Tumors: Wounds That Do Not HealNew England Journal of Medicine, 1986